Mitochondrial biology and the identification of biomarkers of Huntington's disease

被引:6
|
作者
Neueder, Andreas [1 ]
Orth, Michael [1 ,2 ]
机构
[1] Ulm Univ, Dept Neurol, Ulm, Germany
[2] Neurozentrum Siloah, SwissHuntingtons Dis Ctr, Worbstr 312, CH-3073 Gumligenbei Bern, Switzerland
关键词
fission and fusion; huntingtin fragment; mitochondrial quality control; mtDNA; splicing; TRANSCRIPTION FACTOR-A; ISOLATED BRAIN MITOCHONDRIA; CYTOCHROME-C RELEASE; YAC128 MOUSE MODEL; COMPLEX-II DEFECTS; DNA COPY NUMBER; MUTANT HUNTINGTIN; STRIATAL NEURONS; CAG REPEAT; NUCLEAR-LOCALIZATION;
D O I
10.2217/nmt-2019-0033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Apart from finding novel compounds for treating Huntington's disease (HD) an important challenge at present consists in finding reliable read-outs or biomarkers that reflect key biological processes involved in HD pathogenesis. The core elements of HD biology, for example, HTT RNA levels or protein species can serve as biomarker, as could measures from biological systems or pathways in which Huntingtin plays an important role. Here we review the evidence for the involvement of mitochondrial biology in HD. The most consistent findings pertain to mitochondrial quality control, for example, fission/fusion. However, a convincing mitochondrial signature with biomarker potential is yet to emerge. This requires more research including in peripheral sources of human material, such as blood, or skeletal muscle.
引用
收藏
页码:243 / 255
页数:13
相关论文
共 50 条
  • [41] Mitochondrial defect in Huntington's disease on caudate nucleus
    Gu, M
    Gash, MT
    Mann, VM
    JavoyAgid, F
    Cooper, JM
    Schapira, AHV
    ANNALS OF NEUROLOGY, 1996, 39 (03) : 385 - 389
  • [42] Mitochondrial matters of the brain: the role in Huntington’s disease
    C. Turner
    A. H. V. Schapira
    Journal of Bioenergetics and Biomembranes, 2010, 42 : 193 - 198
  • [43] A mitochondrial basis for Huntington’s disease: therapeutic prospects
    J. Chakraborty
    U. Rajamma
    K. P. Mohanakumar
    Molecular and Cellular Biochemistry, 2014, 389 : 277 - 291
  • [44] Salivary Biomarkers for Huntington Disease
    Corey-Bloom, Jody
    Haque, Ameera
    Kim, Aeri
    Park, Sungmee
    Snell, Chase
    Granger, Douglas A.
    Granger, Steven W.
    Thomas, Elizabeth A.
    NEUROTHERAPEUTICS, 2018, 15 (04) : 1174 - 1174
  • [45] Huntington\'s disease: Biology, therapeutic strategies, and translational challenges
    Munoz-Sanjuan, Ignacio
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [46] Biomarkers for the experimental therapeutics of Huntington's disease (HD) and Parkinson's disease (PD)
    Shoulson, I
    BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : 47 - 49
  • [47] MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?
    Dong, Xiaoyu
    Cong, Shuyan
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2021, 15
  • [48] Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington's Disease
    Chang, Kuo-Hsuan
    Cheng, Mei-Ling
    Lo, Chi-Jen
    Fan, Chun-Ming
    Wu, Yih-Ru
    Chen, Chiung-Mei
    CELLS, 2023, 12 (03)
  • [49] Cerebrospinal fluid biomarkers in Huntington's disease - a longitudinal study
    Niemela, V.
    Sundblom, J.
    Landtblom, A. -M.
    Herman, S.
    Kultema, K.
    Nyholm, D.
    Blennow, K.
    MOVEMENT DISORDERS, 2017, 32 (12) : E8 - E8
  • [50] Important Role of Oxidative Stress Biomarkers in Huntington's Disease
    Tunez, Isaac
    Sanchez-Lopez, Fernando
    Agueera, Eduardo
    Fernandez-Bolanos, Ricardo
    Manuel Sanchez, Francisco
    Tasset-Cuevan, Inmaculada
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (15) : 5602 - 5606